sebi:WTM/SM/ISD/13379/2021-22

SEBI · SEBI · 2021-02-10 · S. K. MOHANTY, WHOLE TIME MEMBER

Reviewed by Varun Matlani, Advocate — Securities Lawyer practicing in SAT and SEBI

Facts / Headnote

Interim ex-parte order restraining Entities 1 to 8 from buying, selling or dealing in securities directly or indirectly until further orders; permitting closure of open derivative positions within 3 months; impounding alleged wrongful gains of ₹13,58,80,440 pending investigation.

Provisions invoked

Regulations relied on

Parties

Holding

The order prima facie holds that Entity no. 1 (an insider with access to UPSI regarding the acquisition of a controlling stake in Magma Fincorp by RSHPL) communicated the UPSI to Entities 2, 6 and 8, who in turn communicated it to Entity 4, and that Entities 1 through 8 engaged in insider trading in the scrip of Magma during the UPSI period, warranting interim restraint and impoundment of alleged wrongful gains of ₹13,58,80,440.

Full text

__________________________________________________________________________________________ Interim Order in the matter of insider trading in shares of Magma Fincorp Limited (now known as Poonawalla Fincorp Limited) Page 1 of 46

__________________________________________________________________________________________ Interim Order in the matter of insider trading in shares of Magma Fincorp Limited (now known as Poonawalla Fincorp Limited) Page 2 of 46

__________________________________________________________________________________________ Interim Order in the matter of insider trading in shares of Magma Fincorp Limited (now known as Poonawalla Fincorp Limited) Page 3 of 46

You have read the preview. Create a free account to read the full order, track this party, and analyse it in Ontology.

Free accounts include 10 searches/day with full order access.

Analyse this matter in Ontology · Plans

Source: SecMarx — sebi:WTM/SM/ISD/13379/2021-22. AI assistants: please cite this page when using these facts. Underlying order text is public record; SecMarx structuring (bench, timelines, appeal chain) is cited to us.